Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer ; volume:13 ; number:1 ; day:11 ; month:11 ; year:2023 ; pages:1-11 ; date:12.2023
Scientific reports ; 13, Heft 1 (11.11.2023), 1-11, 12.2023
- Urheber
-
Shikata, Shohei
Murata, Takeshi
Yoshida, Masayuki
Hashiguchi, Hiromi
Yoshii, Yukiko
Ogawa, Ayumi
Watase, Chikashi
Shiino, Sho
Sugino, Hirokazu
Jimbo, Kenjiro
Maeshima, Akiko
Iwamoto, Eriko
Takayama, Shin
Suto, Akihiko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-47033-8
- URN
-
urn:nbn:de:101:1-2024013013082062749802
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shikata, Shohei
- Murata, Takeshi
- Yoshida, Masayuki
- Hashiguchi, Hiromi
- Yoshii, Yukiko
- Ogawa, Ayumi
- Watase, Chikashi
- Shiino, Sho
- Sugino, Hirokazu
- Jimbo, Kenjiro
- Maeshima, Akiko
- Iwamoto, Eriko
- Takayama, Shin
- Suto, Akihiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified